###begin article-title 0
###xml 90 98 <span type="species:ncbi:9606">Patients</span>
Circulating Tissue Inhibitor of Matrix Metalloproteinase-4 (TIMP-4) in Systemic Sclerosis Patients with Elevated Pulmonary Arterial Pressure
###end article-title 0
###begin p 1
Recommended by Yona Keisari
###end p 1
###begin p 2
This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 2
###begin p 3
###xml 705 706 705 706 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 961 962 961 962 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 237 245 <span type="species:ncbi:9606">patients</span>
###xml 594 602 <span type="species:ncbi:9606">patients</span>
###xml 655 663 <span type="species:ncbi:9606">patients</span>
Decreased levels of matrix metalloproteinases (MMPs) or excess levels of their tissue inhibitors (TIMPs) may contribute to dysregulation of extracellular matrix turnover in systemic sclerosis (SSc). In a cross-sectional study of 106 SSc patients, we measured serum levels of TIMP-4 which is preferentially expressed in cardiovascular structures and searched for correlations with simultaneously performed echocardiography measurements of pulmonary artery systolic pressure (PASP), myocardial performance, and pulmonary function tests. TIMP-4, but not MMP-9, levels were significantly raised in patients with SSc than controls. However, in the subgroup of patients with PASP measurements lower to 40 mmHg (n = 69), TIMP-4 levels were comparable to controls irrespective of the presence of diffuse or limited skin involvement, or lung fibrosis. Individual PASP measurements suggestive of pulmonary hypertension were associated with increased TIMP-4 serum levels (P = .03), independently of age, extent of skin sclerosis, or lung fibrosis, suggesting a cardiopulmonary vasculature-specific role of TIMP-4 activation in SSc.
###end p 3
###begin title 4
1. INTRODUCTION
###end title 4
###begin p 5
###xml 258 259 258 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 720 721 720 721 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 723 724 723 724 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 890 891 890 891 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 592 600 <span type="species:ncbi:9606">patients</span>
Systemic sclerosis (SSc) is characterized by excessive accumulation of collagen and other components of extracellular matrix in the skin and internal organs, being perhaps the prototypic disorder of a generalized disruption of connective tissue homeostasis [1]. Vasoconstriction and structural changes of the blood vessels, including intimal proliferation and obstruction, are expressed clinically as Raynaud's phenomenon, digital ulcers, renal disease, cardiac disease, and pulmonary hypertension (PH). Cardiopulmonary complications, including PH which occurs in a significant proportion of patients either as an isolated abnormality or secondary to pulmonary fibrosis, are currently the leading cause of death in SSc [1, 2]. Although effective screening for PH has proven difficult, many experts believe that early detection and intervention may alter the natural history of the disease [3].
###end p 5
###begin p 6
###xml 589 590 589 590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 592 593 592 593 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 696 697 696 697 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 699 700 699 700 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 898 899 898 899 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 621 629 <span type="species:ncbi:9606">patients</span>
###xml 788 796 <span type="species:ncbi:9606">patients</span>
###xml 864 872 <span type="species:ncbi:9606">patients</span>
Connective tissue turnover depends on the balance between the synthesis and degradation of the extracellular matrix. Extracellular matrix degradation is regulated mainly by matrix metalloproteinases (MMP-1 to MMP-28) and an important mechanism for the regulation of their activity is via binding to a family of homologous proteins, the tissue inhibitors of metalloproteinases (TIMP-1 to TIMP-4). Several lines of evidence indicate that the balance between MMPs and TIMPs levels governs connective tissue homeostasis, being a crucial determinant in inflammation, fibrosis and angiogenesis [4, 5]. Fibroblasts derived from patients with SSc produce increased amounts of TIMP-1, TIMP-2, and TIMP-3 [6, 7], whereas expression of MMP-1, MMP-2, and MMP-3 genes is decreased in fibroblasts from patients with early SSc compared to fibroblasts from healthy individuals or patients with late-stage disease [6]. These and other results suggest that excess levels of TIMPs, or decreased levels of MMPs may contribute to matrix accumulation in SSc.
###end p 6
###begin p 7
###xml 309 310 309 310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 428 429 428 429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 431 432 431 432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 551 552 551 552 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 628 630 628 630 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 737 738 737 738 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 956 958 956 958 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 153 158 <span type="species:ncbi:9606">human</span>
###xml 501 509 <span type="species:ncbi:9606">patients</span>
###xml 585 593 <span type="species:ncbi:9606">patients</span>
TIMP-4 is the newest member in the mammalian TIMP family and differs from the other 3 TIMPs by its expression pattern. TIMP-4 is abundantly expressed in human cardiovascular structures, while all other tissues at the normal state, including the lung parenchyma, are characterized by low or absent expression [8]. Animal studies have suggested an important role of TIMP-4 in inflammatory diseases and cardiovascular pathologies [4, 5]. Moreover, TIMP-4 myocardial expression is remarkably increased in patients with aortic stenosis undergoing surgery [9], and in dilated cardiomyopathy patients with deteriorating heart failure [10]. On the other hand, MMP-9 is also found in cardiac myocytes, cardiac fibroblasts, and endocardial cells [4]. Although among other TIMPs there is only little specificity for inhibiting individual MMPs, key factors in every MMP inhibition are the size, charge, and polarity of residue 2 in the particular structure of TIMP-4 [11].
###end p 7
###begin p 8
###xml 317 318 317 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 320 322 320 322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
Based on the above, we hypothesized that aberrant TIMP-4 and/or MMP-9 activation may play a role in cardiovascular complications of SSc. To test this hypothesis, we examined serum levels of these molecules as well as of B-type natriuretic peptide (BNP), an established marker of SSc-related cardiovascular pathology [1, 12], and searched for correlations with echocardiography measurements of pulmonary artery systolic pressure (PASP), myocardial performance, and pulmonary function tests.
###end p 8
###begin title 9
2. PATIENTS AND METHODS
###end title 9
###begin title 10
2.1. Study population
###end title 10
###begin p 11
###xml 819 826 815 822 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tab1">Table 1</xref>
###xml 32 40 <span type="species:ncbi:9606">patients</span>
###xml 46 51 <span type="species:ncbi:9606">women</span>
###xml 432 440 <span type="species:ncbi:9606">patients</span>
###xml 668 676 <span type="species:ncbi:9606">patients</span>
###xml 770 778 <span type="species:ncbi:9606">patients</span>
###xml 1015 1023 <span type="species:ncbi:9606">patients</span>
One hundred and six consecutive patients (102 women) with SSc, aged between 22 and 80 years (mean 54 +/- 13 years) and with disease duration ranging between 2 to 25 years (mean 11 +/- 4 years) from date of the first non-Raynaud's phenomenon SSc manifestation, participated in this cross-sectional study. Blood samples were collected at the day of their regular follow-up which included lung function tests and echocardiography. SSc patients with previous myocardial infarction or stroke, valvular or congenital heart disease, hypertrophic cardiomyopathy, previous history of arterial hypertension, chronic obstructive pulmonary disease, or malignancies, as well those patients receiving bosentan or intravenous iloprost during the last 4 weeks, were excluded. Seventeen patients (15%) were current smokers. As shown in Table 1, medications included calcium-channel blockers in 77%, angiotensin-converting enzyme inhibitors in 55%, corticosteroids in 29%, cyclophosphamide in 22%, and mycophenolate mofetil in 7% of patients.
###end p 11
###begin p 12
###xml 204 206 204 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 208 210 208 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 364 366 364 366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 220 228 <span type="species:ncbi:9606">patients</span>
Pulmonary function tests (Master-Screen Diffusion, Jaeger, Wuerzburg, Germany) included spirometry, total lung capacity (TLC), and carbon monoxide diffusing capacity (DLCO) measurements, as described in [13, 14]. In all patients with both TLC and DLCO lower than 80% of predicted (indicative of pulmonary fibrosis) high resolution computed tomography of the lung [14] performed during the previous 6 months had confirmed the presence of fibrosis.
###end p 12
###begin p 13
###xml 161 163 161 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 292 294 292 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 363 365 363 365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 537 539 537 539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 382 390 <span type="species:ncbi:9606">patients</span>
Complete echocardiographic examination (Hewlet-Packard Sonos 1000 ultrasound system, using a 2.5 MHz transducer) was performed as described in detail elsewhere [15], and established indices of myocardial performance for right and left ventricles (Tei-index) were calculated, as described in [16]. PASP was considered elevated when exceeded the level of 40 mm Hg [17]. There were 37 patients with elevated PASP; 18 of them had undergone right heart catheterization during the previous year confirming the presence of PH secondary to SSc [18] in all.
###end p 13
###begin p 14
###xml 445 446 443 444 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 73 78 <span type="species:ncbi:9606">women</span>
###xml 131 139 <span type="species:ncbi:9606">patients</span>
###xml 345 350 <span type="species:ncbi:9606">women</span>
###xml 426 434 <span type="species:ncbi:9606">patients</span>
Sera collected from 24 age-matched healthy subjects (54 +/- 19 years, 23 women), who fulfilled the exclusion criteria employed for patients, served as controls. All controls underwent a complete examination comprising electrocardiogram, echocardiography and exercise stress to exclude asymptomatic cardiac disease. Of the 24 control subjects, 8 women were current smokers, a marginally higher frequency comparing to 17 of 106 patients with SSc (P = .052). The study protocol was approved by Laikon Hospital and Alexandra Hospital ethics committees and all subjects gave informed consent.
###end p 14
###begin title 15
2.2. Measurements of circulating TIMP-4, MMP-9, and BNP molecules
###end title 15
###begin p 16
###xml 125 130 <span type="species:ncbi:9606">human</span>
###xml 153 158 <span type="species:ncbi:9606">human</span>
###xml 276 283 <span type="species:ncbi:9606">patient</span>
###xml 423 431 <span type="species:ncbi:9606">patients</span>
Circulating levels of TIMP-4 and MMP-9 were measured by quantitative sandwich enzyme-linked immunosorbent assays (Quantikine human TIMP-4 and Quantikine human MMP-9 total, respectively, R&D Systems Inc., Minneapolis, Minn, USA) according to the manufacturer's instructions in patient's and control sera that had been kept at -70 C. BNP concentrations were measured immediately after venipuncture in plasma samples from SSc patients using a sandwich immunoenzymatic assay (Triage BNP test, Biosite, San Diego, Calif, USA), according to the manufacturer's instructions.
###end p 16
###begin title 17
2.3. Statistical analysis
###end title 17
###begin p 18
###xml 73 74 73 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 878 879 876 877 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
Comparisons for continuous variables between groups were performed using t-test or Mann-Whitney test, in case of normal or skewed distribution, respectively. Age-adjusted partial correlation coefficients were built to evaluate examined correlations. TIMP-4, MMP-9/TIMP-4 ratios, and BNP were expressed as log10(TIMP-4), log10(MMP-9/TIMP-4), and log10(BNP), respectively, when correlated or regressed because of their skewed distribution. Bonferroni correction was used in cases of multiple testing to avoid false positive associations. Multivariate regression analysis was used to assess the association of TIMP-4 and/or MMP-9 levels with PASP, after controlling for possible confounders, such as age, presence or not of lung fibrosis, type of skin involvement (diffuse or limited), and BNP. The statistical package used was SPSS 13.0. Values are expressed as mean +/- SD and a P-value < .05 was considered significant.
###end p 18
###begin title 19
3. RESULTS
###end title 19
###begin title 20
3.1. Circulating MMP-9 and TIMP-4 levels and extent of skin or pulmonary fibrosis in SSc
###end title 20
###begin p 21
###xml 190 192 190 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 195 202 195 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tab1">Table 1</xref>
###xml 308 315 308 315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tab2">Table 2</xref>
###xml 11 19 <span type="species:ncbi:9606">patients</span>
###xml 70 78 <span type="species:ncbi:9606">patients</span>
###xml 269 277 <span type="species:ncbi:9606">patients</span>
###xml 355 363 <span type="species:ncbi:9606">patients</span>
Of the 106 patients, 75 had diffuse (truncal skin involvement) and 31 patients had limited SSc (skin sclerosis confined to hands, arms, feet, and face), according to LeRoy's classification [19] (Table 1). Mean values of pulmonary function tests were comparable between patients with diffuse and limited SSc (Table 2); pulmonary fibrosis was present in 46 patients (34 with diffuse SSc).
###end p 21
###begin p 22
###xml 203 214 199 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Figure 1(a)</xref>
###xml 303 304 295 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 54 61 <span type="species:ncbi:9606">patient</span>
###xml 138 146 <span type="species:ncbi:9606">patients</span>
###xml 232 240 <span type="species:ncbi:9606">patients</span>
###xml 359 367 <span type="species:ncbi:9606">patients</span>
MMP-9 levels were not different between the whole SSc patient group and controls (530 +/- 260 ng/mL versus 446 +/- 201 ng/mL, resp.), but patients with diffuse SSc had higher MMP-9 levels than controls (Figure 1(a)) as well as than patients with limited SSc (587 +/- 266 ng/mL versus 393 +/- 182 ng/mL, P = .0003). No significant difference was noted between patients with lung fibrosis and those without (548 +/- 222 ng/mL versus 517 +/- 287 ng/mL).
###end p 22
###begin p 23
###xml 480 491 470 481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Figure 1(b)</xref>
###xml 65 72 <span type="species:ncbi:9606">patient</span>
###xml 214 222 <span type="species:ncbi:9606">patients</span>
###xml 388 396 <span type="species:ncbi:9606">patients</span>
In contrast to MMP-9, TIMP-4 levels were raised in the whole SSc patient group (2035 +/- 1064 pg/mL, range 380-4961 pg/mL) compared to controls (1484 +/- 489 pg/mL, range 683-2661 pg/mL) as well as in subgroups of patients with diffuse (2028 +/- 1100 pg/mL, range 380-4961 ng/mL) or limited SSc (2050 +/- 987 ng/mL, range 694-4900 ng/mL). Also, TIMP-4 levels were significantly higher in patients with pulmonary fibrosis (2157 +/- 1068 ng/mL, range 846-4900 ng/mL) than controls (Figure 1(b)).
###end p 23
###begin p 24
###xml 12 19 12 19 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tab3">Table 3</xref>
###xml 293 301 <span type="species:ncbi:9606">patients</span>
###xml 374 382 <span type="species:ncbi:9606">patients</span>
###xml 434 442 <span type="species:ncbi:9606">patients</span>
As shown in Table 3, age-adjusted partial correlations revealed no significant associations between individual serum levels of MMP-9, TIMP-4, or their ratio with corresponding pulmonary function tests. No significant differences, either for TIMP-4 or for MMP-9 mean levels, were noted between patients receiving, or not, angiotensin-converting enzyme inhibitors, or between patients receiving immunomodulatory drugs and the remaining patients.
###end p 24
###begin title 25
3.2. Elevated pulmonary artery pressure in SSc is associated with increased TIMP-4 levels
###end title 25
###begin p 26
###xml 602 609 598 605 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tab4">Table 4</xref>
###xml 977 988 973 984 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Figure 1(c)</xref>
###xml 1107 1114 1103 1110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tab4">Table 4</xref>
###xml 20 28 <span type="species:ncbi:9606">patients</span>
###xml 367 375 <span type="species:ncbi:9606">patients</span>
###xml 413 421 <span type="species:ncbi:9606">patients</span>
###xml 426 434 <span type="species:ncbi:9606">patients</span>
###xml 511 519 <span type="species:ncbi:9606">patients</span>
###xml 709 717 <span type="species:ncbi:9606">patients</span>
###xml 820 828 <span type="species:ncbi:9606">patients</span>
###xml 946 954 <span type="species:ncbi:9606">patients</span>
###xml 1050 1058 <span type="species:ncbi:9606">patients</span>
###xml 1097 1105 <span type="species:ncbi:9606">patients</span>
Thirty seven of 106 patients with SSc (21 with diffuse and 16 with limited SSc) had PASP measurements equal or higher than 40 mm Hg in echocardiography (range 40-85 mm Hg, mean +/- SD 51 +/- 12 mm Hg). Age, disease duration, digital ulcers, arthritis, esophageal or intestinal involvement, antibodies to Scl-70, and current treatment regimens were comparable between patients with elevated PASP and the remaining patients. Of patients with elevated PASP, 22 had concomitant pulmonary fibrosis; the remaining 15 patients, all with limited SSc, had DLCO reduction as an isolated abnormality. As shown in Table 4, echocardiography-derived measurements of myocardial performance were significantly compromised in patients with elevated PASP measurements secondary to either diffuse or limited SSc, compared to the remaining patients. High BNP blood levels reflecting abnormalities in the cardiopulmonary vasculature were found in many of the studied patients with SSc (depicted in Figure 1(c)). As expected, BNP levels were increased by almost 5-fold in patients with elevated PASP than the remaining patients (Table 4).
###end p 26
###begin p 27
###xml 12 20 12 20 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Figure 2</xref>
###xml 230 231 226 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 458 459 450 451 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 502 503 492 493 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 563 564 551 552 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 610 611 596 597 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 769 770 753 754 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 804 805 786 787 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 862 863 842 843 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 896 897 874 875 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 74 82 <span type="species:ncbi:9606">patients</span>
###xml 178 186 <span type="species:ncbi:9606">patients</span>
###xml 273 281 <span type="species:ncbi:9606">patients</span>
###xml 415 423 <span type="species:ncbi:9606">patients</span>
###xml 514 522 <span type="species:ncbi:9606">patients</span>
###xml 668 676 <span type="species:ncbi:9606">patients</span>
As shown in Figure 2, TIMP-4 serum levels were considerably higher in SSc patients with elevated PASP measurements (2486 +/- 1190 pg/mL, range 850-4961 pg/mL) than the remaining patients (1792 +/- 909 pg/mL, range 380-4862 pg/mL, P = .003). Notably, after excluding the 37 patients with PASP >/=40 mm Hg from the whole SSc group, there were no significant differences in TIMP-4 levels between the control group and patients with diffuse (1767 +/- 929 pg/mL, n = 53) or limited SSc (1875 +/- 862 pg/mL, n = 16), or patients with lung fibrosis (1916 +/- 918 pg/mL, n = 24), or those without (1726 +/- 908 pg/mL, n = 45). TIMP-4 levels differed significantly between SSc patients, when as criterion for abnormally elevated PASP the level of 50 mm Hg (2880 +/- 1174 pg/mL, n = 13, versus 1916 +/- 998 pg/mL, P = .002), or the level of 45 mm Hg (2586 +/- 1283 pg/mL, n = 23 versus 1882 +/- 948 pg/mL, P = .02) was considered.
###end p 27
###begin p 28
###xml 325 333 317 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Figure 2</xref>
###xml 55 63 <span type="species:ncbi:9606">patients</span>
###xml 102 110 <span type="species:ncbi:9606">patients</span>
###xml 211 219 <span type="species:ncbi:9606">patients</span>
In contrast, MMP-9 serum levels were slightly lower in patients with elevated PASP than the remaining patients (511 +/- 265 ng/mL and 541 +/- 258 ng/mL, resp.). MMP-9/TIMP-4 ratios were significantly smaller in patients with elevated PASP (255 +/- 192) than in those with PASP measurements lower than 40 mm Hg (402 +/- 380) (Figure 2).
###end p 28
###begin p 29
###xml 12 19 12 19 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tab3">Table 3</xref>
###xml 708 715 708 715 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tab3">Table 3</xref>
As shown in Table 3, age-adjusted partial correlation coefficients between individual TIMP-4 serum levels and the corresponding levels of PASP revealed a positive significant correlation. Since multiple testing may result to false positive associations, the Bonferroni correction was used, yielding the same results. On the other hand, echocardiographic indicators of either global myocardial performance (Tei-indices), or of left ventricle's systolic function (ejection fraction) did not correlate significantly with TIMP-4 circulating levels. In contrast, increased left ventricle Tei-index, indicative of impaired performance, was associated significantly with lower MMP-9 levels and MMP-9/TIMP-4 ratios (Table 3).
###end p 29
###begin p 30
###xml 353 357 353 354 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;</italic>
###xml 379 380 376 377 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 426 430 423 424 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;</italic>
###xml 452 453 446 447 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 226 234 <span type="species:ncbi:9606">patients</span>
###xml 647 654 <span type="species:ncbi:9606">patient</span>
Finally, stepwise multivariate linear regression analysis was performed to assess possible associations among individual PASP measurements and the 3 corresponding clinical and laboratory parameters under study for the 106 SSc patients. Using this model, we found that increased PASP measurements were associated with TIMP-4 (log transformed-continuous, beta-coefficient = 0.180, P = .031) and BNP (log transformed-continuous, beta-coefficient = 0.534, P < .001). In contrast, no significant associations could be established with age (continuous), MMP-9 (continuous), SSc type (diffuse, limited), or presence of lung fibrosis (no, yes) in our SSc patient cohort.
###end p 30
###begin title 31
4. DISCUSSION
###end title 31
###begin p 32
###xml 966 968 966 968 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 970 972 970 972 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 974 976 974 976 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 1295 1297 1295 1297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 1299 1301 1299 1301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 1316 1318 1316 1318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 73 81 <span type="species:ncbi:9606">patients</span>
###xml 131 139 <span type="species:ncbi:9606">patients</span>
###xml 202 210 <span type="species:ncbi:9606">patients</span>
###xml 259 266 <span type="species:ncbi:9606">patient</span>
###xml 403 411 <span type="species:ncbi:9606">patients</span>
###xml 660 668 <span type="species:ncbi:9606">patients</span>
###xml 1106 1113 <span type="species:ncbi:9606">patient</span>
###xml 1341 1348 <span type="species:ncbi:9606">patient</span>
In the present study, we found that TIMP-4 serum levels are increased in patients with either diffuse or limited SSc as well as in patients with pulmonary fibrosis. Because a relatively large number of patients were available, appropriate comparisons between patient subgroups were possible. No significant differences in TIMP-4 levels were noted between diffuse or limited skin involvement, or between patients with lung fibrosis and those without, suggesting a not convincing association of increased TIMP-4 serum levels with the extent of fibrosis characterizing SSc. However, further analysis showed that increased TIMP-4 circulating levels were higher in patients with elevated PASP measurements in echocardiography, irrespective of skin involvement extent or lung fibrosis. PASP was considered elevated when reaching or exceeding the level of 40 mm Hg in echocardiography, as also reported in other studies using noninvasive assessments of pulmonary pressure [15, 17, 20]. Clearly, echocardiography is not valid for the definite diagnosis of PH, but performing right cardiac catheterization in every patient was not possible. However, similarly significant associations between elevated PASP and TIMP-4 levels were also obtained when higher thresholds suggestive of PH, that is, 45 mm Hg [21, 22] or 50 mm Hg [18], were applied in our patient cohort.
###end p 32
###begin p 33
###xml 223 225 223 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 227 229 227 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 347 349 347 349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 368 370 368 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 378 380 378 380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 389 391 389 391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 451 453 451 453 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 977 979 977 979 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 1054 1056 1054 1056 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 109 117 <span type="species:ncbi:9606">patients</span>
###xml 1044 1052 <span type="species:ncbi:9606">patients</span>
Moreover, individual TIMP-4 levels correlated positively with the corresponding PASP measurements in our 106 patients with SSc. Treatment with angiotensin-converting enzyme inhibitors, known to influence TIMP-4 expression [23, 24], appeared not to affect this result. Age adjustment was applied in statistical analyses because MMP-9 may decrease [25], whereas TIMP-4 [25], BNP [26], PASP [17], and echocardiographic indices of myocardial performance [27] may increase with age. Finally, despite the limitation that serum measurements were performed only once, multivariate linear regression analysis revealed significant associations of PASP elevations and increases of TIMP-4 serum levels, but not with the presence of diffuse or limited SSc, or the presence of lung fibrosis in this cohort. In addition to TIMP-4, PASP was associated with increased BNP blood levels, as expected. Previous studies have shown that BNP levels are directly related to the severity of PH in SSc [12], and may be considered an independent predictor of PH in these patients [28].
###end p 33
###begin p 34
###xml 228 230 228 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 231 233 231 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B34">34</xref>
###xml 319 321 319 321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B32">32</xref>
###xml 323 325 323 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B33">33</xref>
###xml 571 573 571 573 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B34">34</xref>
###xml 74 82 <span type="species:ncbi:9606">patients</span>
###xml 130 138 <span type="species:ncbi:9606">patients</span>
###xml 466 474 <span type="species:ncbi:9606">patients</span>
To the best of our knowledge, no previous studies have examined TIMP-4 in patients with systemic connective tissue diseases or in patients with PH. Regarding TIMP-1 and TIMP-2 serum levels, both have been found elevated in SSc [29-34], and probably increased TIMP-2 levels correlate with cardiopulmonary complications [32, 33]. In a larger study examining both TIMP-1 and TIMP-2, only TIMP-1 levels were significantly elevated in diffuse and limited SSc compared to patients with primary Raynaud's phenomenon or controls, and no association with organ disease was found [34].
###end p 34
###begin p 35
###xml 147 149 147 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B35">35</xref>
###xml 200 202 200 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B36">36</xref>
###xml 204 206 204 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B37">37</xref>
###xml 276 278 276 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B38">38</xref>
###xml 82 90 <span type="species:ncbi:9606">patients</span>
###xml 331 338 <span type="species:ncbi:9606">patient</span>
###xml 531 539 <span type="species:ncbi:9606">patients</span>
On the other hand, MMP-9 levels were significantly raised only in our subgroup of patients with diffuse SSc, in accordance with previous findings [35]. Overexpression of TGF-beta in scleroderma skin [36, 37] may contribute to local MMP-9 induction and proteolytic activation [38], thus resulting in increased circulating levels in patient with extended skin sclerosis. Such increases explain perhaps the trend toward significance of the inverse correlation of MMP-9 levels with DLCO and TLC measurements, since the majority of our patients with pulmonary fibrosis had diffuse SSc.
###end p 35
###begin p 36
###xml 112 114 112 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 133 135 133 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 151 153 151 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B39">39</xref>
###xml 650 652 650 652 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B40">40</xref>
###xml 799 801 799 801 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B41">41</xref>
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
###xml 94 102 <span type="species:ncbi:9606">patients</span>
###xml 187 195 <span type="species:ncbi:9606">patients</span>
###xml 258 266 <span type="species:ncbi:9606">patients</span>
###xml 389 397 <span type="species:ncbi:9606">patients</span>
###xml 702 710 <span type="species:ncbi:9606">patients</span>
Patients with elevated PASP appeared to have lower MMP-9 mean levels, as also reported in SSc patients with PH [21]. Since bosentan [21] and iloprost [39] may attenuate MMP-9 expression, patients receiving such treatments were excluded from our study. Those patients with elevated PASP, most likely due to increased TIMP-4, had significantly smaller MMP-9/TIMP-4 ratios than the remaining patients, suggesting that different remodeling mechanisms of extracellular matrix may operate. Since MMP-9/TIMP-4 ratio reflects better the proteolytic activity, a decreased "net MMP activity" may favor decreased degradation of extracellular matrix components [40] within the cardiopulmonary vasculature in these patients. As shown in an experimental model of PH associated with marked inflammatory component [41], therapeutic inhibition of MMP activity by TIMP-1 gene transfer aggravated PH, indicating that MMPs play a protective role against pulmonary artery remodeling.
###end p 36
###begin p 37
###xml 527 529 527 529 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B42">42</xref>
###xml 705 707 705 707 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B43">43</xref>
###xml 836 838 836 838 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B44">44</xref>
###xml 1039 1041 1039 1041 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B45">45</xref>
###xml 299 314 <span type="species:ncbi:10090">transgenic mice</span>
###xml 860 864 <span type="species:ncbi:10090">mice</span>
###xml 1033 1037 <span type="species:ncbi:10090">mice</span>
Moreover, lower individual MMP-9 levels and smaller MMP-9/TIMP-4 ratios were associated with impaired left ventricle myocardial performance, further implying a role of TIMP-4/MMP-9 interactions in cardiopulmonary vasculature abnormalities in SSc. Interestingly, cardiac remodeling in erythropoietin-transgenic mice, characterized by a stiffer left ventricle with diastolic dysfunction, is associated with decreased MMP-9 and increased TIMP-4 expression, followed by a shift in collagen mRNA expression from type III to type I [42]. It should be noted, however, that TIMPs and MMPs play also a complex role in regulating angiogenesis. For example, while TIMP-4 can induce apoptosis in cardiac fibroblasts [43], it may also act as an inhibitor of capillary endothelial cell migration, but not of proliferation or of angiogenesis in vivo [44]. On the other hand, mice hyperexpressing the profibrotic cytokine TGF-beta develop myocardial fibrosis and have a 2.5 increase of TIMP-4 myocardial expression compared to nontransgenic control mice [45].
###end p 37
###begin title 38
5. CONCLUSION
###end title 38
###begin p 39
###xml 464 466 464 466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B46">46</xref>
###xml 662 663 662 663 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 665 667 665 667 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B47">47</xref>
###xml 572 580 <span type="species:ncbi:9606">patients</span>
The results presented herein may suggest that activation of TIMP-4, perhaps by leading to enhanced interactions with MMPs, plays a role in the increased stiffening within the cardiopulmonary vasculature in SSc. Whether this abnormality is a potential therapeutic target deserves further investigation. As reported recently, TIMP-4 gene was identified as one of 8 candidate genes for SSc in a pilot study using DNA pooling and genetic association analysis methods [46]. Prospective studies to examine whether serum TIMP-4 measurements may be used to identify high-risk SSc patients for cardiopulmonary complications, perhaps in combination with other biomarkers [3, 47], are warranted.
###end p 39
###begin title 40
ACKNOWLEDGMENTS
###end title 40
###begin p 41
This work was supported by grants from the Athens University Medical School (ELKE 157), and the Greek Rheumatology Society.
###end p 41
###begin article-title 42
Mechanisms and consequences of fibrosis in systemic sclerosis
###end article-title 42
###begin article-title 43
Systemic sclerosis: hypothesis-driven treatment strategies
###end article-title 43
###begin article-title 44
Screening and therapy of pulmonary hypertension in systemic sclerosis
###end article-title 44
###begin article-title 45
Designing TIMP (tissue inhibitor of metalloproteinases) variants that are selective metalloproteinase inhibitors
###end article-title 45
###begin article-title 46
###xml 90 95 <span type="species:ncbi:9606">human</span>
Tissue inhibitor of metalloproteinases 4 (TIMP4) is involved in inflammatory processes of human cardiovascular pathology
###end article-title 46
###begin article-title 47
###xml 149 157 <span type="species:ncbi:9606">patients</span>
Gene expression of types I and III collagen, decorin, matrix metalloproteinases and tissue inhibitors of metalloproteinases in skin fibroblasts from patients with systemic sclerosis
###end article-title 47
###begin article-title 48
Activation of tissue inhibitor of metalloproteinases-3 (TIMP-3) mRNA expression in scleroderma skin fibroblasts
###end article-title 48
###begin article-title 49
###xml 42 47 <span type="species:ncbi:9606">human</span>
Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4
###end article-title 49
###begin article-title 50
###xml 99 107 <span type="species:ncbi:9606">patients</span>
Regulation of matrix metalloproteinases and their inhibitors in the left ventricular myocardium of patients with aortic stenosis
###end article-title 50
###begin article-title 51
###xml 125 133 <span type="species:ncbi:9606">patients</span>
A quantitative gene expression profile of matrix metalloproteinases (MMPS) and their inhibitors (TIMPS) in the myocardium of patients with deteriorating heart failure requiring left ventricular assist device support
###end article-title 51
###begin article-title 52
MMP-TIMP interaction depends on residue 2 in TIMP-4
###end article-title 52
###begin article-title 53
Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension
###end article-title 53
###begin article-title 54
Diffusing capacity of the lung and nifedipine in systemic sclerosis
###end article-title 54
###begin article-title 55
###xml 59 62 59 62 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">99m</sup>
###xml 35 40 <span type="species:ncbi:9606">human</span>
Lung scintigraphy with nonspecific human immunoglobulin G (99mTC-HIG) in the evaluation of pulmonary involvement in connective tissue diseases: correlation with pulmonary function tests (PFTs) and high-resolution computed tomography (HRCT)
###end article-title 55
###begin article-title 56
Aortic stiffness in systemic sclerosis is increased independently of the extent of skin involvement
###end article-title 56
###begin article-title 57
Doppler echocardiographic index for assessment of global right ventricular function
###end article-title 57
###begin article-title 58
Clinical correlates and reference intervals for pulmonary artery systolic pressure among echocardiographically normal subjects
###end article-title 58
###begin article-title 59
Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis
###end article-title 59
###begin article-title 60
Scleroderma (systemic sclerosis): classification, subsets and pathogenesis
###end article-title 60
###begin article-title 61
Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival
###end article-title 61
###begin article-title 62
###xml 63 71 <span type="species:ncbi:9606">patients</span>
The effect of bosentan on matrix metalloproteinase-9 levels in patients with systemic sclerosis-induced pulmonary hypertension
###end article-title 62
###begin article-title 63
Pulmonary arterial hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interstitial lung disease
###end article-title 63
###begin article-title 64
###xml 64 68 <span type="species:ncbi:10116">rats</span>
MMP/TIMP expression in spontaneously hypertensive heart failure rats: the effect of ACE- and MMP-inhibition
###end article-title 64
###begin article-title 65
###xml 104 107 <span type="species:ncbi:10116">rat</span>
Effect of ramipril and furosemide treatment on interstitial remodeling in post-infarction heart failure rat hearts
###end article-title 65
###begin article-title 66
Effects of age on plasma matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs)
###end article-title 66
###begin article-title 67
Plasma brain natriuretic peptide concentration: impact of age and gender
###end article-title 67
###begin article-title 68
Age dependency of the Tei index of myocardial performance
###end article-title 68
###begin article-title 69
###xml 195 203 <span type="species:ncbi:9606">patients</span>
High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis
###end article-title 69
###begin article-title 70
The association of serum matrix metalloproteinases and their tissue inhibitor levels with scleroderma disease severity
###end article-title 70
###begin article-title 71
###xml 60 68 <span type="species:ncbi:9606">patients</span>
Serum levels of tissue inhibitor of metalloproteinases 2 in patients with systemic sclerosis
###end article-title 71
###begin article-title 72
Clinical outcomes of bosentan in pulmonary arterial hypertension do not correlate with levels of TIMPs
###end article-title 72
###begin article-title 73
###xml 146 154 <span type="species:ncbi:9606">patients</span>
Correlation of endostatin and tissue inhibitor of metalloproteinases 2 (TIMP2) serum levels with cardiovascular involvement in systemic sclerosis patients
###end article-title 73
###begin article-title 74
###xml 60 68 <span type="species:ncbi:9606">patients</span>
Serum levels of tissue inhibitors of metalloproteinase 2 in patients with systemic sclerosis with duration more than 2 years: correlation with cardiac and pulmonary abnormalities
###end article-title 74
###begin article-title 75
###xml 35 43 <span type="species:ncbi:9606">patients</span>
Serum TIMP-1, TIMP-2, and MMP-1 in patients with systemic sclerosis, primary Raynaud's phenomenon, and in normal controls
###end article-title 75
###begin article-title 76
###xml 39 47 <span type="species:ncbi:9606">patients</span>
Elevated matrix metalloproteinase-9 in patients with systemic sclerosis
###end article-title 76
###begin article-title 77
###xml 63 67 63 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;</italic>
###xml 92 100 <span type="species:ncbi:9606">patients</span>
Immunohistological demonstration of transforming growth factor-beta isoforms in the skin of patients with systemic sclerosis
###end article-title 77
###begin article-title 78
Skin involvement in scleroderma: where histological and clinical scores meet
###end article-title 78
###begin article-title 79
###xml 27 31 27 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;</italic>
###xml 59 64 56 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 124 129 <span type="species:ncbi:9606">human</span>
Transforming growth factor-beta- and tumor necrosis factor-alpha -mediated induction and proteolytic activation of MMP-9 in human skin
###end article-title 79
###begin article-title 80
Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension
###end article-title 80
###begin article-title 81
Excess matrix accumulation in scleroderma is caused partly by differential regulation of stromelysin and TIMP-1 synthesis
###end article-title 81
###begin article-title 82
###xml 121 125 <span type="species:ncbi:10116">rats</span>
Inhibition of matrix metalloproteinases by lung TIMP-1 gene transfer or doxycycline aggravates pulmonary hypertension in rats
###end article-title 82
###begin article-title 83
###xml 37 52 <span type="species:ncbi:10090">transgenic mice</span>
Cardiac remodeling in erythropoietin-transgenic mice
###end article-title 83
###begin article-title 84
Tissue inhibitor of metalloproteinase-4 instigates apoptosis in transformed cardiac fibroblasts
###end article-title 84
###begin article-title 85
Modulation of angiogenesis by tissue inhibitor of metalloproteinase-4
###end article-title 85
###begin article-title 86
###xml 50 54 50 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;</italic>
###xml 61 65 58 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;</italic>
###xml 68 83 <span type="species:ncbi:10090">transgenic mice</span>
Myocardial fibrosis in transforming growth factor-beta1 (TGF-beta1) transgenic mice is associated with inhibition of interstitial collagenase
###end article-title 86
###begin article-title 87
Whole genome association by DNA pooling leads to interesting candidate genes for systemic sclerosis
###end article-title 87
###begin article-title 88
Lymphocyte adhesion molecules in autoimmune rheumatic diseases: basic issues and clinical expectations
###end article-title 88
###begin p 89
###xml 56 64 <span type="species:ncbi:9606">patients</span>
###xml 141 149 <span type="species:ncbi:9606">patients</span>
 (a) MMP-9, (b) TIMP-4, and (c) BNP blood levels in SSc patients with diffuse (dSSc) and limited (lSSc) skin involvement as well as in those patients with pulmonary fibrosis (PF+) compared to healthy controls (Mann-Whitney test, NS denotes nonsignificant).
###end p 89
###begin p 90
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
###xml 178 186 <span type="species:ncbi:9606">patients</span>
Patients with SSc and elevated pulmonary artery systolic pressure (PASP >/= 40 mm Hg) have higher TIMP-4 levels and smaller MMP-9/TIMP-4 ratios (bars show SD) than the remaining patients (Mann-Whitney test).
###end p 90
###begin p 91
###xml 20 28 <span type="species:ncbi:9606">patients</span>
 Characteristics of patients with systemic sclerosis (SSc).
###end p 91
###begin p 92
###xml 55 91 53 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">number of patients with less than 80</italic>
###xml 93 105 91 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">of predicted</italic>
###xml 65 73 <span type="species:ncbi:9606">patients</span>
###xml 110 118 <span type="species:ncbi:9606">patients</span>
 Pulmonary function tests (mean +/- SD of % predicted, number of patients with less than 80% of predicted) in patients with systemic sclerosis (SSc).
###end p 92
###begin p 93
FEV1: forced expiratory volume at 1 second;
###end p 93
###begin p 94
FVC: forced vital capacity;
###end p 94
###begin p 95
TLC: total lung capacity;
###end p 95
###begin p 96
DLCO: diffusing lung capacity for carbon monoxide.
###end p 96
###begin p 97
###xml 35 36 35 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 118 126 <span type="species:ncbi:9606">patients</span>
Age-adjusted partial correlations (r) of MMP-9, TIMP-4 and their ratio with respiratory and cardiac indicators in 106 patients with systemic sclerosis. Levels of significance are shown in parentheses.
###end p 97
###begin p 98
FEV1: forced expiratory volume at 1 second;
###end p 98
###begin p 99
FVC: forced vital capacity;
###end p 99
###begin p 100
TLC: total lung capacity;
###end p 100
###begin p 101
DLCO: diffusing lung capacity for carbon monoxide;
###end p 101
###begin p 102
PASP: pulmonary artery systolic pressure;
###end p 102
###begin p 103
BNP: B-type natriuretic peptide;
###end p 103
###begin p 104
RV: right ventricular;
###end p 104
###begin p 105
LV: left ventricular;
###end p 105
###begin p 106
EF: ejection fraction;
###end p 106
###begin p 107
NS denotes nonsignificant.
###end p 107
###begin p 108
###xml 106 114 <span type="species:ncbi:9606">patients</span>
Echocardiography-derived measurements of myocardial performance and BNP blood levels (mean +/- SD) in SSc patients with normal or elevated PASP.
###end p 108
###begin p 109
SSc: systemic sclerosis;
###end p 109
###begin p 110
PASP: pulmonary artery systolic pressure;
###end p 110
###begin p 111
BNP: B-type natriuretic peptide;
###end p 111
###begin p 112
RV: right ventricular;
###end p 112
###begin p 113
LV: left ventricular;
###end p 113
###begin p 114
EF: ejection fraction.
###end p 114
###begin p 115
###xml 14 22 <span type="species:ncbi:9606">patients</span>
*Comparing to patients with PASP </=40.
###end p 115

